A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

June 4, 2020

Study Completion Date

June 4, 2020

Conditions
Plaque Psoriasis
Interventions
DRUG

Ixekizumab

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (17)

100020

Beijing Chao Yang Hospital, Beijing

100034

Peking University First Hospital, Beijing

100044

Peking University People's Hospital, Beijing

100191

Peking University Third Hospital, Beijing

110001

The First Hospital of China Medical University, Shenyang

130022

The Second Hospital of Jilin University, Changchun

200025

Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai

200443

Shanghai Dermatology Hospital, Shanghai

210029

The First Affiliated Hospital with Nanjing Medical University, Nanjing

224005

YanCheng First People's Hospital, Yancheng

310009

Second Affiliate Hospital of Zhejiang Medical University, Hangzhou

310014

Zhejiang Provincial People's Hospital, Hangzhou

410011

The Second Xiangya Hospital of Central South University, Changsha

510080

Guangdong Province People's Hospital, Guangzhou

610041

West China Hospital of Sichuan University, Chengdu

710004

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an

030001

First Hospital of Shanxi Medical University, Taiyuan

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03364309 - A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter